ArticleTranslational oncology2017
Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.
Article in Translational oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- The Roles of TNF Signaling Pathways in Metabolism of Bone Tumors.Frontiers in pharmacology · 2022Pooled it
- Microenvironment matters: insights from the FOSTER consortium on microenvironment-driven approaches to osteosarcoma therapy.Cancer metastasis reviews · 2025Review
- An improved experimental model of osteosarcoma lung metastases to investigate innovative therapeutic interventions and sex as a biological variable.International journal of pharmaceutics · 2025Article
- Construction of a novel cancer-associated fibroblast-related signature to predict clinical outcome and immune response in cervical cancer.Translational oncology · 2024Article
- The Relationship between PBLS and Osteosarcoma Distribution in Different Subgroups and the Survival and Prognosis of Osteosarcoma.Journal of oncology · 2023Article
- Recent Progress on the Role of Fibronectin in Tumor Stromal Immunity and Immunotherapy.Current topics in medicinal chemistry · 2022Review
- TYROBP, TLR4 and ITGAM regulated macrophages polarization and immune checkpoints expression in osteosarcoma.Scientific reports · 2021Article
- Article
- Alternative splicing of leptin receptor overlapping transcript in osteosarcoma.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- Osteosarcoma-Derived Extracellular Vesicles Induce Lung Fibroblast Reprogramming.International journal of molecular sciences · 2020Article
- Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma.World journal of surgical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The targeted delivery of tumor necrosis factor-α (TNF-α) with antibodies specific to splice isoforms of fibronectin [e.g., F8-TNF, specific to the extra-domain A (EDA) domain of fibronectin] has already shown efficacy against experimental sarcomas but has not yet been investigated in orthotopic sarcomas. Here, we investigated F8-TNF in a syngeneic K7 M2-derived orthotopic model of osteosarcoma as a treatment against pulmonary metastases, the most frequent cause of osteosarcoma-related death. Immunofluorescence on human osteosarcoma tissue confirmed the presence of EDA in primary tumors (PTs) as well as metastases. In mice, the efficacy of F8-TNF against PTs and early pulmonary metastases was evaluated. Intratibial PT growth was not affected by F8-TNF, yet early micrometastases were reduced possibly due to an F8-TNF-dependent attraction of pulmonary CD4
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.